0000000000186448

AUTHOR

Armando Perrotta

showing 2 related works from this author

The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment

2019

Background: Central neuropathic pain represents one of the most common symptoms in multiple sclerosis (MS) and it seriously affects quality of life. Spinal mechanisms may contribute to the pathogenesis of neuropathic pain in MS. Converging evidence from animal models and neurophysiological and clinical studies in humans suggests a potential effect of transcranial direct current stimulation (tc-DCS) on neuropathic pain. Spinal application of DCS, i.e., transcutaneous spinal DCS (ts-DCS), may modulate nociception through inhibition of spinal reflexes. Therefore, ts-DCS could represents an effective, safe and well-tolerated treatment for neuropathic pain in MS, a largely unexplored topic. This…

transcutaneous spinal direct current stimulation (ts-DCS)nociceptive withdrawal reflexmedicine.medical_treatmentnon-invasiveWithdrawal reflexmultiple sclerosis050105 experimental psychologylcsh:RC321-57103 medical and health sciencesBehavioral Neuroscience0302 clinical medicinemedicine0501 psychology and cognitive sciencesSpasticitylcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryOriginal Researchneuropathic painTranscranial direct-current stimulationbusiness.industryMultiple sclerosis05 social sciencesmedicine.diseaseNeuromodulation (medicine)Psychiatry and Mental healthNeuropsychology and Physiological PsychologyNociceptionNeurologyAnesthesianeuromodulationNeuropathic painmultiple sclerosis; neuromodulation; neuropathic pain; nociceptive withdrawal reflex; non-invasive; transcutaneous spinal direct current stimulation (ts-DCS)Reflexmedicine.symptombusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in Human Neuroscience
researchProduct

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, par…

2011

Medication-overuse headache (MOH) represents a severely disabling condition, with a low response to prophylactic treatments. Recently, consistent evidences have emerged in favor of botulinum toxin type-A (onabotulinum toxin A) as prophylactic treatment in chronic migraine. In a 12-week double-blind, parallel group, placebo-controlled study, we tested the efficacy and safety of onabotulinum toxin A as prophylactic treatment for MOH. A total of 68 patients were randomized (1:1) to onabotulinum toxin A (n = 33) or placebo (n = 35) treatment and received 16 intramuscular injections. The primary efficacy end point was mean change from baseline in the frequency of headache days for the 28-day per…

AdultMalemedicine.medical_specialtyNeurologyOriginalPain medicineClinical NeurologyBotulinum toxin type-APlaceboInjections Intramuscularlaw.inventionChronic MigraineRandomized controlled trialDouble-Blind MethodlawmedicineHumansBotulinum Toxins Type AAdverse effectMuscle SkeletalBotulinum toxin type-A; Medication-overuse headache; Prophylactic treatment; Migraine; Pericranial muscle tendernessMigraineAgedAnalgesicsbusiness.industrySkullHeadacheGeneral MedicineMiddle Agedmedicine.diseaseBotulinum toxinMedication-overuse headacheAnesthesiology and Pain MedicinePericranial muscle tendernessMigraineNeuromuscular AgentsAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessProphylactic treatmentmedicine.drugThe journal of headache and pain
researchProduct